These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Exploring gastrointestinal manifestations in childhood onset systemic lupus erythematosus - Insights from a multicenter study.
    Author: Sönmez HE, Batu ED, İşgüder R, Şahin N, Aliyev E, Aslan E, Çoban S, Güngörer V, Karadağ ŞG, Karaçayır N, Kısaoğlu H, Yekedüz Bülbül A, Garip S, Karalı Y, Ayduran S, Demir S, Kaya Akça Ü, Başaran Ö, Şahin S, Kasap B, Kilic SS, Kışla Ekinci RM, Kısaarslan AP, Kalyoncu M, Bakkaloğlu S, Yüksel S, Aktay Ayaz N, Çelikel Acar B, Sözeri B, Kasapçopur Ö, Ünsal E, Özen S.
    Journal: Lupus; 2024 Oct; 33(12):1358-1364. PubMed ID: 39186467.
    Abstract:
    OBJECTIVE: Systemic lupus erythematosus (SLE) constitutes an autoimmune disorder with potential involvement of the gastrointestinal system (GIS). Our objective was to assess the gastrointestinal (GI) manifestations in patients diagnosed with childhood onset SLE. METHODS: The study cohort consisted of 123 patients with childhood onset-SLE and GIS involvement from 16 referral departments of pediatric rheumatology. All participants met the Systemic Lupus International Collaborating Clinics criteria. RESULTS: Out of 123 patients, 78 (63.4%) exhibited GIS involvement at the initial SLE diagnosis, whereas the remaining 45 (36.6%) developed GI symptoms after a median duration of 12 (3-140) months. Eighty-two (66.7%) individuals experienced symptoms related to the GI tract, whereas the remaining patients received a diagnosis of GI involvement through laboratory assessments. The predominant initial GIS involvement symptom was abdominal pain, observed in 77 (62.6%) patients, followed by elevated hepatic transaminases in 70 (56.9%), hepatomegaly in 40 (32.5%), diarrhea in 26 (21.1%), and jaundice in 11 (8.9%) patients. The GIS involvement was associated with SLE in 82 (78.6%), while it resulted from drug-related adverse events in 35 (28.5%) patients or comorbidities in 6 (0.5%) patients. CONCLUSION: GIS involvement should be considered in all childhood onset-SLE patients, especially in the presence of suggestive symptoms or elevated hepatic transaminases. It is also crucial to consider SLE in the differential diagnosis of GIS manifestations in children. Apart from GIS involvement directly associated with SLE, adverse events of drugs should be kept in mind.
    [Abstract] [Full Text] [Related] [New Search]